Endo appoints Shane M. Cooke to Board of Directors
DUBLIN, July 30, 2014
DUBLIN, July 30, 2014 /PRNewswire/ --Endo International plc (NASDAQ: ENDP)
(TSX: ENL) today announced the appointment of Shane M. Cooke to the company's
board of directors. Mr. Cooke, an international business leader with more
than 25 years of experience, currently serves as president of Alkermes plc
based in Dublin, Ireland. Mr. Cooke has also been appointed to Endo's Audit
and Transactions Committee.
"I am excited to welcome Shane to our board of directors," said Roger Kimmel,
chairman of the board of Endo. "He brings exceptional experience in the areas
of finance, biotechnology as well as pharmaceutical operations. Our board is
looking forward to the perspective Shane will provide related to our strategy
and business operations as we continue to focus on delivering value for our
customers and shareholders."
Mr. Cooke joined Alkermes as president upon completion of the merger between
Elan Drug Technologies (EDT) and Alkermes, Inc. in September 2011. Previously,
he was head of EDT and executive vice president of Elan from 2007 through the
merger in 2011 and concurrently served as chief financial officer of Elan
Corporation from 2001 to May 2011. Mr. Cooke was appointed director of Elan in
May 2005. Prior to joining Elan, he was chief executive of Pembroke Capital
Limited, an aviation leasing company of which he was a founder. Mr. Cooke also
previously held a number of senior positions in finance in the banking and
Mr. Cooke is a chartered accountant and a graduate of University College
Dublin, Ireland. He currently serves on the board of directors of Prothena
About Endo International plc
Endo International plc is a global specialty healthcare company focused on
improving patients' lives while creating shareholder value. Endo develops,
manufactures, markets, and distributes quality branded pharmaceutical, generic
and device products through its operating companies. Endo has global
headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA. Learn
more at www.endo.com .
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 and Canadian securities
legislation. Statements including words such as "believes," "expects,"
"anticipates," "intends," "estimates," "plan," "will," "may," "look forward,"
"intend," "guidance," "future" are forward-looking statements. Because these
statements reflect our current views, expectations and beliefs concerning
future events, these forward-looking statements involve risks and
uncertainties. Although Endo believes that these forward-looking statements
and information are based upon reasonable assumptions and expectations,
readers should not place undue reliance on them, or any other forward looking
statements or information in this news release. Investors should note that
many factors, as more fully described in the documents filed by Endo with
securities regulators in the United States and Canada including under the
caption "Risk Factors" in Endo Health Solutions Inc.'s ("EHSI") Form 10-K, and
Endo's Form 10-Q and Form 8-K filings, as applicable, with the Securities and
Exchange Commission and with securities regulators in Canada on the System for
Electronic Document Analysis and Retrieval ("SEDAR") and as otherwise
enumerated herein or therein, could affect Endo's future financial results and
could cause Endo's actual results to differ materially from those expressed in
forward-looking statements contained in EHSI's Annual Report on Form 10-K. The
forward-looking statements in this press release are qualified by these risk
factors. These are factors that, individually or in the aggregate, could cause
our actual results to differ materially from expected and historical results.
Endo assumes no obligation to publicly update any forward-looking statements,
whether as a result of new information, future developments or otherwise,
except as may be required under applicable securities law.
Contact: Investors/Media: Blaine Davis, +353-1-669-6635, +1 (484) 219-7158;
Media: Heather Zoumas Lubeski, +1 (484) 216-6829; Investors: Jonathan Neely,
+1 (484) 216-6645
Press spacebar to pause and continue. Press esc to stop.